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Abstract
Introduction: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. Alefacept
(a lymphocyte function-associated antigen (LFA)-3 Ig fusion protein that binds to CD2 and functions as an
antagonist to T-cell activation) has been shown to result in improvement in psoriasis but has limited effectiveness
in PsA. Interleukin-20 (IL-20) is a key proinflammatory cytokine involved in the pathogenesis of psoriasis. The effects
of alefacept treatment on IL-20 expression in the synovium of patients with psoriasis and PsA are currently
unknown.
Methods: Eleven patients with active PsA and chronic plaque psoriasis were treated with alefacept (7.5 mg per
week for 12 weeks) in an open-label study. Skin biopsies were taken before and after 1 and 6 weeks, whereas
synovial biopsies were obtained before and 4 and 12 weeks after treatment. Synovial biopsies from patients with
rheumatoid arthritis (RA) (n = 10) were used as disease controls. Immunohistochemical analysis was performed to
detect IL-20 expression, and stained synovial tissue sections were evaluated with digital image analysis. Double
staining was performed with IL-20 and CD68 (macrophages), and conversely with CD55 (fibroblast-like
synoviocytes, FLSs) to determine the phenotype of IL-20-positive cells in PsA synovium. IL-20 expression in skin
sections (n = 6) was analyzed semiquantitatively.
Results: IL-20 was abundantly expressed in both PsA and RA synovial tissues. In inflamed PsA synovium, CD68+
macrophages and CD55+ FLSs coexpressed IL-20, and its expression correlated with the numbers of FLSs. IL-20
expression in lesional skin of PsA patients decreased significantly (P = 0.04) 6 weeks after treatment and correlated
positively with the Psoriasis Area and Severity Index (PASI). IL-20 expression in PsA synovium was not affected by
alefacept.
Conclusions: Conceivably, the relatively limited effectiveness of alefacept in PsA patients (compared with anti-
tumor necrosis factor (TNF) therapy) might be explained in part by persistent FLS-derived IL-20 expression.
Introduction
Psoriatic arthritis (PsA) is an inflammatory joint disease
associated with psoriasis, characterized by a heteroge-
neous clinical presentation including spinal involvement,
peripheral synovitis, and enthesitis. Cellular infiltration
plays an important role in the induction of inflammation
in joint tissues, as well as in psoriatic skin [1].
Alefacept is a lymphocyte function-associated antigen
(LFA)-3 immunoglobulin (Ig) fusion protein that binds to
CD2 and functions as an antagonist to T-cell activation.
Alefacept was the first of the biologic agents to be approved
in the United States for the treatment of adult patients with
moderate-to-severe chronic plaque psoriasis who are candi-
dates for systemic therapy or phototherapy. This fully
human fusion protein inhibits activation of memory T cells
(CD45RO+), a subpopulation of lymphocytes that plays a
critical role in the pathogenesis of psoriasis [2]. This ther-
apy has been shown to be effective in patients with psoriasis
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[3], and it also has some efficacy in PsA [4,5] compared
with anti-TNF therapy. Clinical response, as determined by
the American College of Rheumatology 20 (ACR20)
response at week 24, was achieved by a significantly greater
proportion of patients receiving alefacept plus methotrexate
(54%) compared with those receiving placebo plus metho-
trexate (23%), but proportions of patients achieving ACR50
and ACR70 responses at week 24 were not significantly dif-
ferent in a randomized, double-blind, placebo-controlled
study in 185 PsA patients [5].
Interleukin-20 (IL-20) belongs to the IL-10 cytokine
family. IL-20 receptor (IL-20R) and IL-20 are expressed
in several normal tissue types, including the lungs, skin,
and kidney [6,7]. Moreover, IL-20 has been implicated
to play an important role in several autoimmune dis-
eases that include rheumatoid arthritis (RA), lupus
nephritis, and Crohn disease (reviewed in [8]). Recent
reports have shown that IL-20 functions as a proinflam-
matory cytokine in several inflammatory diseases, of
which psoriasis has been the most extensively studied
[9,10]. IL-20 gene and protein expression was elevated
in lesional psoriatic skin compared with normal and
nonlesional skin [11-13]. Interestingly, its expression in
PsA has as yet not been investigated. IL-20 is expressed
mainly by activated monocytes [14]. Other sources of
IL-20 are keratinocytes (KCs) [14,15], maturing dendritic
cells (DCs) [16], synovial fibroblasts [17], endothelial
cells [18,19], and renal mesangial cells [20]. IL-20 signals
through two alternative receptor complexes: type I,
which is composed of IL-20R1/IL-20R2 chains, and type
II, which consists of an IL-22R/IL-20R2 heterodimer
[21]. IL-20R1, IL-20R2, and IL-22R chains are coex-
pressed at high levels in the skin [7,22]. In addition,
KCs [23,24], rheumatoid synovium (fibroblasts and
synovial fluid cells) [17,24,25], and endothelial cells [17]
express IL-20R chains. The interaction between IL-20
and its receptors leads to various biologic effects that
include hyperproliferation of KCs [7], production of
inflammatory cytokines and chemokines by synovial
fibroblasts [17] and KCs [7], neutrophil chemotaxis, and
angiogenesis [17]. Recently, a role for IL-20 in osteoclast
differentiation was reported [26].
Decreased expression of IL-20 in the skin has been
observed after effective treatment with calcipitriol,
cyclosporine [22], and infliximab [27]. Of interest,
reduced IL-20 expression has also been demonstrated in
the skin of patients after alefacept treatment [13], but
only in those who responded clinically (12 responders
versus eight nonresponders). Thus, these initial data sug-
gest that IL-20 might serve as a biomarker associated
with efficacy in patients with psoriasis. Here, we extend
the findings for the skin of patients with psoriasis and
demonstrate for the first time the effects of alefacept
treatment on IL-20 expression in the synovium of
patients with PsA. Moreover, in view of these data, it is
clear that IL-20 is a key proinflammatory cytokine for
both skin and synovium. The unique use of paired skin
and synovium from patients with PsA (with active psoria-
sis) allowed us to address the question whether alefacept
treatment leads to a specific tissue-response mechanism.
Methods
Patients and tissue samples
Skin and synovial biopsy specimens were obtained from
patients with chronic plaque psoriasis and PsA (n = 11
synovial biopsies; n = 6 skin biopsies) in a prospective
open-label clinical trial, as previously described [4]. Clin-
ical characteristics have been previously reported [4].
Patients received a weekly dose of alefacept (LFA-3TIP,
anti-CD2; Amevive, Biogen, San Diego, CA, USA; 7.5
mg, intravenously) for 12 weeks. In brief, skin biopsies
were taken before and after 1 and after 6 weeks, whereas
synovial biopsies were taken before and 4 and 12 weeks
after treatment. Synovial biopsy specimens from active
RA patients (Table 1; n = 10) served as disease control
group for IL-20 expression at baseline. Patient’s disease
activity score (DAS28), visual analogue scale (VAS) for
global disease activity (scale, 0 to 100 mm), swollen-
joint count (SJC), tender-joint count (TJC), erythrocyte
sedimentation rate (ESR), and serum levels of C-reactive
protein (CRP) were used to evaluate disease activity.
The study was conducted according to International
Conference of Harmonization (ICH)/Declaration of Hel-
sinki, approved by the Medical Ethics Committee of
Academic Medical Center (AMC)/University of Amster-
dam, and all patients gave written informed consent.
Psoriasis area and severity index (PASI) was assessed as
previously described [28].
Synovial and skin biopsy immunohistochemical staining
All samples were, immediately after collection,
embedded en bloc in Tissue Tec OCT (Miles, Elkhart,
IN, USA) and subsequently snap frozen. The frozen
blocks were stored in liquid nitrogen until processed.
Table 1 Demographic and clinical characteristics of RA
patients at baseline
RA patients
Sex, female/male (n) 8/2 (10)
Age in years, mean (range) 55.5 (44-64)
DAS28 4.9 (2.9-6.5)
SJC, mean (range) 11.7 (6-18)
TJC, mean (range) 9.8 (1-16)
VAS, mean (range) 22 (10-32)
CRP (mg/l), mean (range) 21 (3-52)
ESR mm/h, mean (range) 23.9 (3-74)
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Shortly before staining, 5-μm sections were cut and
mounted on glass slides (Star Frost; Knittelgläser,
Braunschweig, Germany). The glass slides were sealed
and stored at -80ºC until immunohistochemical analysis
was performed.
In brief, after fixation with acetone, endogenous peroxi-
dase activity was inhibited by using 0.1% sodium azide and
0.3% hydrogen peroxide in phosphate-buffered saline
(PBS). The primary antibody against human IL-20 (Zymo-
genetics, Seattle, WA, USA) was incubated overnight at
4ºC followed by secondary antibody affinity-purified horse-
radish peroxidase (HRP)-conjugated goat anti-mouse
(Dako Cytomation, Glostrup, Denmark) for 30 minutes,
followed by subsequent incubation with biotinylated tyra-
mide (Perkin Elmer, Boston, MA, USA) for 30 minutes
and HRP-conjugated streptavidin for 30 minutes. HRP
activity was detected by using hydrogen peroxide as sub-
strate and amino ethylcarbazole (AEC; SK-4200; Vector
Laboratories, Burlingame, CA, USA) as dye. With this pro-
cedure, IL-20-positive cells stained red. Slides were coun-
terstained with Mayer hematoxylin (Merck, Darmstadt,
Germany) and, after washing with distilled water, mounted
in Kayser glycerol gelatin (Merck).
To identify IL-20-expressing cells in PsA synovial tissue,
double staining was performed by using anti-IL-20 anti-
body together with FITC-labeled anti-CD55 (M2192;
Sanquin Reagents, Amsterdam, The Netherlands) or
FITC-labeled anti-CD68 (clone KP1; Dakocytomation).
Fixation and blocking endogenous peroxidase activity was
performed as stated earlier. The primary antibody against
human IL-20 (Zymogenetics) was incubated overnight at
4ºC followed by secondary antibody affinity-purified horse-
radish peroxidase (HRP)-conjugated goat anti-mouse
(Dako Cytomation) for 30 minutes, and subsequent incu-
bation with biotinylated tyramide (Perkin Elmer) for
30 minutes and HRP-conjugated streptavidin for 30 min-
utes. After a blocking step of 15 minutes with 10% mouse
serum (Sanquin Reagents), FITC-labeled anti-CD55 or
FITC-labeled anti-CD68 was added to the sections and
incubated for 1 hour at room temperature. Then the sec-
tions were incubated for 30 minutes with rabbit anti-FITC
followed by alkaline phosphatase-conjugated swine anti-
rabbit secondary antibodies (both from Dako Cytomation).
HRP activity was detected as stated earlier. Alkaline phos-
phatase activity was detected by using the Alkaline Phos-
phatase Substrate III kit (SK-5300; Vector Laboratories).
With this procedure, IL-20-positive cells stained red,
CD55- or CD68-positive cells stained blue, and double-
positive cells stained purple.
Quantification of IL-20-expressing cells in skin and
synovium
Skin biopsy specimens were scored semiquantitatively for
IL-20 expression on a 5-point scale by two independent
observers who were not aware of the clinical data. The
scoring methods were described previously [29]. In brief,
a score of 0 represented minimal staining, whereas a
score of 4 represented widespread expression of IL-20 in
this case. Individual readings were identical or differed by
only 1 point. Minor differences between the observers
were resolved by mutual agreement.
Quantification of IL-20-expressing cells in PsA and RA
synovial tissues was performed with computer-assisted
image analysis, as previously described [30]. The same
holds true for CD68 and CD55 quantification. In brief,
after immunohistochemical staining, all coded sections
(one section per patient per time point) were randomly
analyzed (18 high-power fields from different parts of the
section were analyzed; for example, the mean of the 18
high-power fields was calculated). The images of the high-
power fields were analyzed by using the Qwin analysis sys-
tem (Leica, Cambridge, UK). Positive staining of CD68
and CD55 was expressed as positive cells/mm2. Positive
staining for IL-20 was expressed as integrated optical den-
sity (IOD/mm2).
Statistical analysis
SPSS version 15.0 for Windows (SPSS, Chicago, IL, USA)
was used for statistical analysis. The Wilcoxon signed
ranks test was used for comparison of nonparametric vari-
ables in related samples, and the Mann-Whitney U test
was used for comparison of nonparametric variables in
independent samples. Correlations between synovial IL-20
expression and disease activity score 28 (DAS28), synovial
CD4, CD8, CD68, and CD55 were analyzed with Spear-
man rank correlation. Correlations between skin IL-20
and PASI were analyzed with Spearman rank correlation.
Results
Expression of IL-20 in PsA and RA synovia
First we analyzed whether IL-20 expression in PsA and RA
synovia differ from each other. IL-20 was expressed in the
intimal lining layer, in the synovial sublining, and on
endothelium in both PsA and RA patients (Figure 1A).
Digital image analysis of synovial tissue demonstrated
clear IL-20 expression with comparable overall scores in
both patient groups (median Integrated Optical Density
(IOD) (range)): PsA, 60,064 (1,588 to 567,696); RA, 68,554
(1,171 to 530,218) (Figure 1B). Double staining of inflamed
PsA synovium showed that CD68+ macrophages and
CD55+ FLS coexpress IL-20 (Figure 1C).
Alefacept treatment does not affect IL-20 expression in
PsA synovium
As previously described, alefacept treatment resulted in
clinical improvement and in a reduction of CD4+ T cells
and CD68+ macrophages in the synovial infiltrate [4].
Despite the clinical improvement and change in cellular
Lebre et al. Arthritis Research & Therapy 2012, 14:R200
http://arthritis-research.com/content/14/5/R200
Page 3 of 8
infiltrate [4], no change was found in IL-20 expression in
the synovium before and after treatment (Figure 2A and
2B). As CD68+ macrophages and CD55+ FLSs express IL-
20, we investigated whether the levels of synovial IL-20
were associated with the numbers of these cells present
in synovial tissue. Although no correlation was present
between the levels of IL-20 and the numbers of both
total CD68+ and sublining CD68+ macrophages (data not
shown), the levels of IL-20 were positively correlated
with the numbers of CD55+ FLSs (r = 0.4238; P =
0.0196). In addition, the levels of synovial IL-20 expres-
sion were not correlated with disease-activity parameters:
DAS28, C-reactive protein (CRP), and erythrocyte sedi-
mentation rate (ESR) (data not shown).
Decreased IL-20 expression in PsA skin lesions after
alefacept treatment
In contrast to findings in the synovium, IL-20 expres-
sion in PsA lesional skin was significantly decreased (P
= 0.04) 6 weeks after alefacept treatment (Figure 3A and
3B). IL-20 expression in PsA lesional skin was positively
correlated with disease activity (PASI score): r = 0.5062;
P = 0.031 (Figure 3C).
Discussion
Here we show that IL-20 is expressed in PsA synovium,
similar to the levels in RA synovium. In PsA inflamed
synovium, both CD68+ macrophages and CD55+ FLSs
coexpress IL-20. This study is the first to investigate the
effects of alefacept treatment on IL-20 expression in
paired synovial tissue and psoriatic lesional skin of
patients with both PsA and psoriasis. Whereas IL-20
expression in PsA synovium was not affected by alefa-
cept treatment, its expression in lesional skin was signif-
icantly decreased after this treatment. In addition, in
psoriatic lesional skin, IL-20 expression was positively
correlated with disease activity (PASI) at baseline and
after treatment. In contrast, synovial IL-20 expression
was not correlated with disease-activity parameters
(DAS28, CRP, ESR; data not shown). The observed
expression of IL-20 in both PsA and RA synovial tissues
is consistent with previous observations showing com-
parable levels of this proinflammatory cytokine in syno-
vial fluid of patients with RA compared with those with
spondyloarthritides, including PsA [24]. These data sug-
gest that synovial IL-20 expression is a feature of various
inflammatory rheumatic diseases.
As reported for RA [17,24], we found that both macro-
phages and FLSs are a source of IL-20 in the synovium of
PsA patients. The exact biologic effects of synovial IL-20
have yet to be determined, but it is tempting to speculate
that this cytokine might affect cells present in inflamed
synovium. Consistent with this notion, it was reported
that IL-20 induced the production of IL-6 and IL-8 and
Figure 1 IL-20 is expressed in PsA and RA synovial tissues. (A) Representative immunohistochemical staining of baseline IL-20 expression in synovial
tissue from PsA and RA patients. Arrows indicate expression of IL-20 in both lining and sublining. (B) Quantification of IL-20 expression in RA and PsA
synovial tissues. Results are shown as median IOD (integrated optical density)/mm2 × 105 of 10 patients with RA and 11 patients with PsA. (C) Double-
immunohistochemistry stainings of IL-20 (red) and CD68+ macrophages (blue) and CD55+ FLS (blue) in PsA synovium. A representative double
immunostaining of PsA synovium from one patient is shown. Arrows indicate double-positive cells. Original magnification, ×200. CRP, C-reactive protein;
DAS28, disease activity score; ESR, erythrocyte sedimentation rate; SJC, swollen-joint count; TJC, tender-joint count; VAS, visual analogue scale (100 mm).
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monocyte chemoattractant protein 1 by FLSs [17]. A
considerable amount of evidence suggests that FLSs are
key cells that contribute to RA pathogenesis. In this way,
IL-20 could play a role in perpetuating the inflammatory
process by promoting the release of inflammatory cyto-
kines and chemokines at the site of inflammation [17].
Alefacept treatment resulted in changes in synovial
inflammation in PsA patients that included a significant
reduction in CD4+ lymphocytes, CD8+ lymphocytes, and
CD68+ sublining macrophages [4], supporting the
hypothesis that T cells orchestrate synovial inflammation
in PsA. However, the expression of synovial IL-20 was
not affected by alefacept treatment, in contrast to the
findings in the skin. This may be explained by the fact
that alefacept treatment did not affect the numbers of
intimal macrophages or the CD55+ FLSs [4]; both cell
types are sources of IL-20, but only the numbers of
CD55+ FLSs were positively correlated with the levels of
synovial IL-20. Together, the data show that alefacept
treatment does not affect the major cellular source of
IL-20 in the synovium (FLSs), in contrast to the findings
in the skin. Of note, alefacept treatment has been aban-
doned as a treatment of PsA, consistent with its limited
clinical efficacy compared with TNF-a-targeted therapies
[31-33]. As discussed, alefacept treatment was associated
with decreased IL-20 expression in lesional psoriatic skin.
As alefacept targets T cells, it is tempting to speculate
that in the skin, T cells are involved in the proximal regu-
lation of IL-20. It is well established that in psoriasis skin,
cross-talk between infiltrating T cells and resident KCs is
Figure 2 Alefacept treatment does not affect IL-20 expression in PsA synovium. (A) Representative immunohistochemical staining of IL-20
in the synovium of a PsA patient. (B) Quantification of IL-20 expression in PsA synovium. Results are shown as median IOD (integrated optical
density)/mm2 × 105 of 11 patients with PsA. (C) Correlation between the expression of IL-20 and the number of CD55+ FLSs in PsA synovium.
Original magnification, ×200. Each dot represents the mean of the 18 high-power fields per patient per time point. CRP, C-reactive protein;
DAS28, disease activity score; ESR, erythrocyte sedimentation rate; SJC, swollen-joint count; TJC, tender-joint count; VAS, visual analogue scale
(100 mm).
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involved in disease pathogenesis [34]. In addition, it was
recently reported that T cell-derived cytokines (IL-17 and
IL-22) mediate IL-20 production by KCs [35]. Thus, in
psoriatic skin of PsA patients, alefacept may affect KC-
derived IL-20 by decreasing the number of infiltrating
T cells that interact with KCs.
Conclusions
IL-20 has been implicated in several inflammatory dis-
eases. The results presented here show that IL-20 is
expressed in psoriatic skin lesions and synovial tissue
from patients with both psoriasis and PsA. It remains to
be established whether the observed effects of alefacept
are specific for IL-20 or also are seen with other mem-
bers of the IL-10 subfamily (IL-19 and IL-24). Conceiva-
bly, the limited effectiveness of alefacept in PsA patients
compared with anti-TNF therapy [31-33] might be
explained in part by persistent IL-20 production by sub-
lining macrophages and FLSs in the synovium.
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